TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Major Shareholder Equity Ab Frankenius Acquires 62,972 Shares of Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) major shareholder Equity Ab Frankenius bought 62,972 shares of TriSalus Life Sciences stock in a transaction dated Tuesday, December 17th. The stock was purchased at an average price of $3.97 per share, with a total value of $249,998.84. Following the completion of the purchase, the insider now owns 6,230,748 shares in the company, valued at $24,736,069.56. This trade represents a 1.02 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

TriSalus Life Sciences Stock Down 4.3 %

Shares of TriSalus Life Sciences stock opened at $3.60 on Friday. TriSalus Life Sciences, Inc. has a 1 year low of $3.50 and a 1 year high of $10.42. The stock has a fifty day moving average price of $4.14 and a 200-day moving average price of $4.96.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TLSI. Oppenheimer started coverage on shares of TriSalus Life Sciences in a research report on Monday, September 16th. They set an “outperform” rating and a $10.00 target price for the company. Roth Mkm started coverage on TriSalus Life Sciences in a report on Monday, November 11th. They set a “buy” rating and a $11.00 price target for the company. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Finally, Northland Securities assumed coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 target price for the company. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, TriSalus Life Sciences presently has a consensus rating of “Buy” and a consensus target price of $11.79.

Hedge Funds Weigh In On TriSalus Life Sciences

Several institutional investors have recently added to or reduced their stakes in TLSI. Highbridge Capital Management LLC bought a new stake in TriSalus Life Sciences in the second quarter worth about $1,184,000. Duquesne Family Office LLC raised its holdings in shares of TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after purchasing an additional 110,966 shares during the period. Geode Capital Management LLC lifted its stake in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after purchasing an additional 62,542 shares during the last quarter. Wolverine Asset Management LLC bought a new position in TriSalus Life Sciences during the second quarter valued at $240,000. Finally, MSD Partners L.P. bought a new position in shares of TriSalus Life Sciences during the 3rd quarter worth $184,000. Institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.